Horizon Pharma plc Announces Pricing of Private Offering of Senior Notes
October 20, 2016 07:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Oct. 20, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP) (“Horizon”), a biopharmaceutical company focused on improving patients’ lives by identifying, developing,...
Horizon Pharma plc Announces Proposed Private Offering of Senior Notes and Intention to Borrow Incremental Term Loans under its Existing Senior Secured Credit Facility
October 13, 2016 07:45 ET
|
Horizon Pharma plc
DUBLIN, Ireland , Oct. 13, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP) (“Horizon”), a biopharmaceutical company focused on improving patients’ lives by identifying, developing,...
Horizon Pharma plc Named One of the Country's Best Medium Workplaces by Fortune Magazine
October 13, 2016 07:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Oct. 13, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Horizon Pharma plc to Host Third-Quarter 2016 Conference Call and Webcast on November 7, 2016
October 11, 2016 16:05 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Oct. 11, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Horizon Pharma plc Provides Update on PBM Formulary Status for Primary Care Medicines
September 29, 2016 08:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Sept. 29, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...
Horizon Pharma plc to Acquire Raptor Pharmaceutical Corp. as Further Step in Building Leading Rare Disease Business
September 12, 2016 07:00 ET
|
Horizon Pharma plc; Raptor Pharmaceutical Corp.
- Transaction valued at $9.00 per share in cash with fully diluted equity value of approximately $800 million - - Transaction is expected to be accretive to adjusted...
Horizon Pharma plc to Participate in Morgan Stanley Global Healthcare Conference
September 06, 2016 07:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering RAYOS® (prednisone) Delayed-Release Tablets
August 18, 2016 07:00 ET
|
Horizon Pharma, Inc.
DUBLIN, Ireland, Aug. 18, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...
Horizon Pharma plc Announces Second-Quarter 2016 Financial Results
August 08, 2016 07:00 ET
|
Horizon Pharma, Inc.
-- Second-Quarter 2016 Record Net Sales of $257.4 Million, Up 49 Percent ---- Second-Quarter 2016 GAAP Net Income of $15.0 Million; Adjusted EBITDA of $121.1 Million ---- Confirms Full-Year 2016 Net...
Horizon Pharma plc to Host Second-Quarter 2016 Conference Call and Webcast on August 8, 2016
July 07, 2016 07:00 ET
|
Horizon Pharma, Inc.
DUBLIN, Ireland, July 07, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...